The Board of NATCO Pharma Limited met in Hyderabad and adopted the consolidated audited accounts of the company for the year ended 31st March, 2016.
NPL recorded an aggregate of Rs.1152.38 crores in consolidated net revenues for the year ended on 31st March, 2016, as against Rs.840.18 crores for last year, with a year-over-year growth of 37.15% in the topline. The net profit, after tax, on a consolidated basis, was recorded as Rs.155.19 crores for the year ended 31st March, 2016, as against Rs.134.61 for the previous year.
For the fourth quarter (Q4) ended March 31st, 2016, the Company recorded a net revenue of Rs.408.47 crores, on a consolidated basis, as against Rs.204 crores during Q4, FY 2015, posting an increase of about 100%. The profit after tax, on a consolidated basis, was recorded as Rs.60.24 crores for the quarter. The key driver for the accelerated revenue growth was the company’s Hepatitis C portfolio of products in the domestic Indian market.
